Aliya Khan
Clinical Professor, Medicine

Aliya Aziz Khan, MD, FRCPC, FACP, FACE, FASBMR

Aliya A. Khan is a Clinical Professor of Medicine, Divisions of Endocrinology and Metabolism and Geriatrics at McMaster University and Director of the Calcium Disorders Clinic at McMaster University Medical Centre. She is also the Director of the Fellowship program in Metabolic Bone Disease at McMaster University.

She graduated from the University of Ottawa Medical School with Honors at age 22. She trained in Internal Medicine, Geriatric Medicine and Endocrinology at the University of Toronto and also completed a research fellowship in Calcium and Metabolic Bone disorders at the University of Toronto.

She has over 200 scientific publications on osteoporosis and parathyroid disease as well as numerous book chapters. She is the Editor or Co-Editor of a number of textbooks including the Handbook of Parathyroid Diseases and the Textbook Bone Metabolism, Parathyroid Gland and Calciotropic Hormones.

She is the founding chair of the annual Canadian Endocrine Update Scientific symposia as well as the Day in Endocrinology for primary care. Dr. Khan led the development of the Canadian position paper on the diagnosis and management of hypophosphatasia. She is leading the development of a national registry and a Canadian position paper in the management of X-linked hypophosphatemia.

Dr. Khan co-chaired the 3rd and 4th International Workshops on Primary Hyperparathyroidism proceedings published in JCEM in 2009 and 2014 respectively . Dr Khan led the development of the international standards of care for hypoparathyroidism published in 2019.

Dr. Khan has led the development of medical management options in Primary Hyperparathyroidism including the 1st international study on the use of alendronate in primary hyperparathyroidism as well as the phase 3 trial on the use of cinacalcet in primary hyperparathyroidism. She is currently investigating the use of various PTH molecules in the management of hypoparathyroidism in phase 1, phase 2 and phase 3 clinical trials. She is the principal investigator evaluating the epidemiology, presentation, management and complications of hypoparathyroidism in the Canadian National Hypoparathyroidism Registry.

Dr. Khan is the Chair of the Rapid Response Committee of Osteoporosis Canada as well as the Co-chair of the Knowledge Translation committee of Osteoporosis Canada. She is a Scientific Advisor of the International Osteoporosis Foundation and Chair of the International Osteonecrosis of the Jaw Task Force. She led the development of the first international position paper on the diagnosis, prevention and management of osteonecrosis of the jaw published in 2015 in JBMR.

She formed the Canadian Panel of the ISCD and was a board member of the ISCD as well as the past Chair of the Credentials Committee of the ISCD. She led the development of the Canadian Standards for the diagnosis of osteoporosis in men, women and children. She also led the development of the Canadian standards for BMD scan acquisition, interpretation and application for physicians and technologists. Published in JCD in 2002 -2007.

In 2019 Dr. Khan was appointed as the Canadian Ambassador for the American Society of Bone and Mineral Research. She is also serving on the Professional Practice Committee of the ASBMR.

Dr. Khan has received numerous national and international awards including the International Clinician Instructor of the Year 2011 award by the International Society of Clinical Densitometry. The Queen’s Diamond Jubilee Medal for 2012 for excellence in clinical care, research and teaching as well as the International Hypoparathyroidism Award for 2014 and the International Osteoporosis Foundation award for publishing excellence in 2017. In 2019 she was recognized as being in the top 0.1% of the world experts in hyperparathyroidism by Expertscape. In 2020 she was recognized for her outstanding contributions to the field of osteoporosis research and education in Canada by Osteoporosis Canada and awarded the Lindy Fraser award.